About us
Research
Lowcountry Infectious Diseases conducts clinical research and provides novel pharmaceutical therapies for many types of infectious diseases. The clinical research trials are conducted in our office or hospital setting to provide volunteers with access to treatment options that may not be available to the public.
Our Clinical Trials
Nontuberculous Mycobacterial (NTM) Lung Infection caused by Mycobacterium Avium Complex (MAC)
ENCORE - A randomized, double-blind, placebo-controlled, active comparator, multicenter study to evaluate the efficacy and safety of an Amikacin Liposome Inhalation Suspension (ALIS)-based regimen in adult subjects with newly diagnosed nontuberculous mycobacterial (NTM) lung infection caused by mycobacterium avium complex (MAC).
Treatment-Refractory Mycobacterium Avium Complex Lung Disease
A phase 2/3, randomized, double-blind, placebo-controlled, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of orally administered epetraborole in patients with treatment-refractory mycobacterium avium complex lung disease (MACrO2).
Clostridioides Difficile Infection
A phase 2, randomized, double-blind, comparator-controlled, multicenter study to evaluate the safety and efficacy of CRS3123 compared with oral vancomycin in adults with clostridioides difficile infection.
Chronic Lymphocytic Leukemia
Double-blind, randomized, placebo-controlled, prospective phase III study evaluating efficacy and safety of panzyga in primary infection prophylaxis in patients with chronic lymphocytic leukemia ("pro-sid" study).
Pulmonary Nontuberculous Mycobacterial Infection
A randomized, double-blind, placebo-controlled phase 2/3 study of the efficacy and safety of treatment with MNKD-101 (Clofazimine Inhalation Suspension) in combination with guideline-based therapy in patients with pulmonary nontuberculous mycobacterial infection followed by an open-label extension.
Recurrent Clostridioides Difficile Infection
A randomized, double-blind, placebo-controlled phase 3 study of VE303 for prevention of recurrent clostridioides difficile infection.
Thank You
We just want to thank all of our patients, referring providers, and our community for bearing with us during this most difficult and unprecedented time in our infectious diseases' careers. Our providers and staff have been spread thin since COVID emerged, spending almost 100% of their time treating the severely ill in our community hospitals up and down the coast of South Carolina. We are doing our best to get back in the office as quickly as possible. Please help us get there quicker by getting vaccinated. Thank you for your patience.